Etoposide Injection IP 100 MG
VEPELIEVA Etoposide Injection IP 100MG is a widely used anticancer chemotherapy medicine formulated for the treatment of different types of cancers. It contains Etoposide, an effective oncology medicine that helps slow down or stop the growth of cancer cells in the body. This injection is commonly used in hospitals, cancer treatment centers, and oncology clinics under the supervision of experienced healthcare professionals.
Etoposide belongs to a class of medicines known as topoisomerase inhibitors. It works by interfering with the DNA replication process of rapidly growing cancer cells. By damaging the DNA of these abnormal cells, the medicine helps prevent their growth and spread. Due to its effectiveness in chemotherapy treatment protocols, Etoposide Injection IP 100MG is commonly prescribed in combination with other anticancer medicines for better treatment outcomes.
VEPELIEVA is manufactured under high pharmaceutical quality standards to ensure safety, purity, and effectiveness. The medicine is designed to meet the requirements of modern oncology treatment and is trusted by healthcare professionals for use in multiple cancer therapies.
This oncology injection is mainly recommended for patients diagnosed with cancers such as small cell lung cancer, testicular cancer, leukemia, lymphoma, and other severe malignant conditions. Doctors may prescribe this medicine alone or as part of combination chemotherapy depending on the patient’s medical condition, stage of cancer, and overall treatment plan.
Chemotherapy medicines like VEPELIEVA are an important part of cancer management because they help reduce the spread of cancer cells and improve the effectiveness of treatment protocols. Since cancer cells multiply rapidly, medicines like Etoposide are specially designed to target these abnormal cells and reduce their growth inside the body.
VEPELIEVA Etoposide Injection IP 100MG is intended strictly for medical use and should only be administered by trained healthcare professionals in clinical settings. Patients are advised not to self-administer this injection. Proper medical monitoring, laboratory testing, and regular health assessments are usually recommended during chemotherapy treatment to ensure patient safety and better treatment response.
This anticancer injection is known for its role in advanced oncology treatment plans and is considered an important chemotherapy medicine in cancer care. With proper medical supervision and supportive care, Etoposide Injection can help improve treatment management in cancer patients.
View Details
Capecitabine Dispersible Tablets 500mg
CAPELIEVA-DT 500 MG (Capecitabine Dispersible Tablets 500 mg) is an oral chemotherapy medicine used in the treatment of various cancers, including colorectal cancer, breast cancer, and gastric cancer. It contains Capecitabine 500 mg, a fluoropyrimidine antineoplastic agent that is converted into its active form, 5-Fluorouracil (5-FU), within the body. This targeted conversion allows the medicine to interfere with cancer cell growth and multiplication while supporting effective cancer management.
Cancer cells grow and divide much faster than normal cells. Capecitabine works by disrupting DNA synthesis in rapidly dividing cells, preventing tumor growth and slowing the progression of cancer. Because the active medicine is produced in higher concentrations within tumor tissues, Capecitabine has become an important component of modern cancer treatment protocols.
CAPELIEVA-DT 500 MG is formulated as a dispersible tablet, offering greater convenience for patients who may have difficulty swallowing conventional tablets. The tablet can be dispersed according to the instructions provided by healthcare professionals, ensuring easier administration and better treatment compliance.
This medicine is widely prescribed by oncologists for patients diagnosed with:
• Colorectal Cancer
• Colon Cancer
• Rectal Cancer
• Metastatic Colorectal Cancer
• Breast Cancer
• Metastatic Breast Cancer
• Gastric (Stomach) Cancer
• Gastroesophageal Cancer
• Advanced Solid Tumors
• Combination Chemotherapy Programs
Capecitabine may be used alone or alongside other anticancer medicines depending on the patient's condition, cancer stage, and treatment goals. It is frequently included in personalized cancer treatment plans designed to improve outcomes and support long-term disease control.
Manufactured under stringent pharmaceutical quality standards, CAPELIEVA-DT 500 MG provides reliable therapeutic performance, safety, and consistency. The medicine should only be used under the supervision of qualified oncologists or healthcare professionals experienced in cancer care.
Patients receiving Capecitabine therapy often require regular blood tests, liver function monitoring, kidney assessments, and medical evaluations to ensure safe and effective treatment. These routine assessments help healthcare providers monitor treatment response and identify any potential side effects early.
Due to its proven effectiveness and convenience as an oral chemotherapy option, CAPELIEVA-DT 500 MG remains an important part of modern oncology treatment programs worldwide.
View Details
Irinotecan Hydrochloride Injection 100mg
IRILIEVA 100 MG (Irinotecan Hydrochloride Injection 100 mg) is a prescription anticancer medicine used in the treatment of various solid tumors, particularly colorectal cancer. It contains Irinotecan Hydrochloride 100 mg, a chemotherapy agent that belongs to the class of medicines known as topoisomerase I inhibitors. The medicine works by interfering with the DNA replication process of cancer cells, helping to slow or stop their growth and spread.
Cancer cells divide rapidly and continuously. Irinotecan targets these rapidly multiplying cells by blocking the activity of an enzyme called topoisomerase I, which is essential for DNA replication and cell division. As a result, cancer cells are unable to reproduce effectively and eventually die, helping to control tumor growth and disease progression.
IRILIEVA 100 MG is widely used in modern oncology treatment protocols and may be administered alone or in combination with other chemotherapy medicines. It plays a significant role in the treatment of advanced and metastatic cancers, particularly gastrointestinal malignancies.
This medicine is commonly prescribed for:
• Metastatic Colorectal Cancer
• Advanced Colon Cancer
• Rectal Cancer
• Gastrointestinal Cancers
• Combination Chemotherapy Protocols
• Advanced Solid Tumors
• Oncology Treatment Programs
• Long-Term Cancer Management
Irinotecan is often included in internationally recognized chemotherapy regimens and may be combined with other anticancer medicines to improve treatment effectiveness and patient outcomes.
Manufactured under stringent pharmaceutical quality standards, IRILIEVA 100 MG is designed to provide reliable therapeutic performance, safety, and consistency. The medicine should only be administered by qualified healthcare professionals in hospitals, oncology centers, or specialized treatment facilities.
Patients receiving Irinotecan therapy typically require regular blood tests, liver function monitoring, kidney assessments, and medical evaluations to ensure safe and effective treatment. These assessments help monitor treatment response and identify potential side effects at an early stage.
Due to its proven effectiveness in cancer treatment, IRILIEVA 100 MG remains an important component of modern chemotherapy and oncology care programs worldwide.
View Details
Topotecan Injection IP 2.5mg
HYCALIEVA 2.5 MG (Topotecan Injection IP 2.5 mg) is a prescription anticancer medicine used for the treatment of specific types of cancer, including ovarian cancer, small cell lung cancer (SCLC), and cervical cancer. It contains Topotecan 2.5 mg, a potent chemotherapy agent belonging to the class of medicines known as topoisomerase I inhibitors. The medicine works by interfering with the DNA replication process in cancer cells, helping to slow tumor growth and prevent the spread of cancer.
Cancer develops when abnormal cells multiply uncontrollably. These rapidly dividing cells require continuous DNA replication to survive and spread. Topotecan blocks an enzyme called topoisomerase I, which plays a critical role in DNA repair and replication. By inhibiting this enzyme, HYCALIEVA 2.5 MG causes damage to cancer cell DNA, leading to cell death and reduced tumor progression.
Topotecan is widely used in oncology treatment programs and may be prescribed when certain cancers recur, progress after previous treatment, or require additional chemotherapy support. It is commonly administered in hospitals, cancer centers, and specialized oncology facilities under the supervision of trained healthcare professionals.
HYCALIEVA 2.5 MG is commonly prescribed for:
• Ovarian Cancer
• Recurrent Ovarian Cancer
• Small Cell Lung Cancer (SCLC)
• Relapsed Small Cell Lung Cancer
• Advanced Cervical Cancer
• Metastatic Cancer Management
• Combination Chemotherapy Protocols
• Oncology Treatment Programs
The medicine may be used alone or in combination with other anticancer agents depending on the type of cancer, stage of disease, and individual treatment goals.
Manufactured under strict pharmaceutical quality standards, HYCALIEVA 2.5 MG is designed to provide reliable therapeutic performance, safety, and consistency. The injection should only be administered by qualified healthcare professionals experienced in chemotherapy and cancer care.
Patients receiving Topotecan therapy typically require routine blood tests, liver and kidney function monitoring, and regular medical assessments to evaluate treatment response and manage potential side effects.
Due to its established role in cancer treatment, HYCALIEVA 2.5 MG remains an important component of modern oncology care and chemotherapy protocols.
View Details
Doxorubicin Hydrochloride iInjection IP 50mg
DOXLIEVA 50 mg contains Doxorubicin Hydrochloride, an anthracycline antitumor antibiotic. It acts by intercalating into DNA, inhibiting topoisomerase II, and generating free radicals, leading to DNA damage and apoptosis of cancer cells. It is a backbone drug in many chemotherapy regimens.
View Details
Dactinomycin for Injection USP 0.5MG
DACTOLIEVA 0.5 mg contains Dactinomycin (Actinomycin D), an antitumor antibiotic. It works by intercalating into DNA, thereby inhibiting RNA synthesis and blocking protein production, leading to cancer cell death. It is especially effective in pediatric and germ cell tumors.
View Details
Vinorelbine Injection IP 50mg
NAVELIEVA 50 mg contains Vinorelbine, a semi-synthetic vinca alkaloid. It inhibits microtubule assembly by binding to tubulin, thereby arresting cell division in the M phase of the cell cycle. It is primarily used in lung and breast cancers.
View Details
Fludarabine Phosphate for Injection 10mg
FLULIEVA 10 mg contains Fludarabine Phosphate, a purine nucleoside analogue antimetabolite. Inside the cell, it is converted to the active metabolite fludarabine triphosphate, which inhibits DNA polymerase, ribonucleotide reductase, and DNA primase, leading to inhibition of DNA synthesis and apoptosis. It is primarily used in hematological malignancies.
View Details
L-Asparaginase Injection 5000IU
L-GANASELIEVA 5,000 IU contains L-Asparaginase, an antineoplastic enzyme used mainly in leukemia treatment. It works by depleting the amino acid asparagine from the blood. Leukemic lymphoblasts cannot synthesize asparagine on their own, so depletion leads to inhibition of protein synthesis and cell death.
View Details
L-Asparaginase Injection 10000IU
L-GANASELIEVA 10,000 IU contains L-Asparaginase, an antineoplastic enzyme. It works by depleting asparagine, an amino acid essential for leukemic lymphoblasts. Normal cells can synthesize asparagine, but leukemic cells cannot—leading to selective tumor cell death.
View Details
Ifosfamide for Injection with Mesna 2g
IFOSLIEVA 2 g contains Ifosfamide, an alkylating antineoplastic agent (nitrogen mustard derivative), supplied with Mesna. Ifosfamide causes DNA cross-linking, inhibiting DNA replication and leading to cancer cell death. Mesna is co-administered to prevent hemorrhagic cystitis by neutralizing toxic metabolites (acrolein) in the urinary tract.
View Details
Ifosfamide for Injection with Mesna 1g
IFOSLIEVA 1 g contains Ifosfamide, an alkylating antineoplastic agent (nitrogen mustard derivative), supplied with Mesna. Ifosfamide causes DNA cross-linking, inhibiting DNA replication and leading to cancer cell death. Mesna is co-administered to prevent hemorrhagic cystitis by binding toxic uro-metabolites (acrolein) in the urinary tract.
View Details
